# US 2016/0354411 A1 · Olivamine-induced improvement in endothelial cells viability and function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354411 A1
- Document ID: US20160354411A1
- Status: Published application
- Kind: A1
- Application number: 14/731,441
- Filed: 2015-06-05
- Published: 2016-12-08
- Earliest claimed: 2015-06-05
- Inventors: Darlene E. McCord
- Web page: https://patentgrep.com/patent/US20160354411A1

## CPC

- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- A61L 26/0057: {Ingredients of undetermined constitution or reaction products thereof}
- A61L 26/0066: {Medicaments; Biocides}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61L 2300/412: Tissue-regenerating or healing or proliferative agents
- A61L 2300/64: Animal cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions for and methods of improving wound healing are disclosed, including compositions for and methods of treating chronic wounds, and compositions for the inhibition and treatment of necrosis and extended quiescence that result in cellular necrosis instead of normal proliferation. The compositions include hydroxytyrosol, oleuropein, or a combination of hydroxytyrosol and oleuropein with endothelial cells. The invention further encompasses methods involving administration of these compositions.

## Claims

### Claim at position 1

1: A composition for accelerating wound closure to improve wound healing comprising:
an effective amount of hydroxytyrosol, or oleuropein, or a combination of hydroxytyrosol and oleuropein; and
an effective amount of primary vascular endothelial cells.

### Claim at position 2 (depends on 1)

2: The composition of claim 1, wherein the administration of the composition reduces the time required for healing of the wound by at least about 30% in comparison to a wound treated with the endothelial cells alone.

### Claim 3

(canceled)

### Claim at position 4 (depends on 1)

4: The composition of claim 1, wherein the primary vascular endothelial cells are derived from umbilical cord blood and are umbilical cord stem cells, or wherein said endothelial cells are provided in the form of a medium conditioned by endothelial cells or growth factors which are beneficially increased as a result of an endothelial stem cell transplant.

### Claim at position 5 (depends on 1)

5: The composition of claim 1 wherein said primary vascular endothelial cells are human endothelial cells.

### Claim at position 6 (depends on 5)

6: The composition of claim 5 wherein said human endothelial cells are microvascular endothelial cells.

### Claim at position 7 (depends on 1)

7: The composition according to claim 1, wherein the ratio of hydroxytyrosol to oleuropein is front about 1:1 to about 10:1.

### Claim at position 8 (depends on 1)

8: The composition according to claim 1, wherein the composition further comprises N-acetyl cysteine, glycine, taurine and L-proline.

### Claim at position 9 (depends on 8)

9: The composition according to claim 8, wherein the weight ratio of N-acetyl cysteine to hydroxytyrosol is between 1:1 and 50:1, wherein the weight ratio of glycine to hydroxytyrosol is between 1:1 and 50:1, wherein the ratio of taurine to hydroxytyrosol is between 1:1 and 50:1, and wherein the weight ratio of L-proline to hydroxytyrosol is between 1:1 and 20:1.

### Claim at position 10 (depends on 9)

10: The composition according to claim 9, wherein the composition has a concentration of hydroxytyrosol less than 225 μM and a concentration of oleuropein less than 900 μM.

### Claim at position 11 (depends on 9)

11: The composition according to claim 9, wherein the composition has a concentration of hydroxytyrosol less than 15 μM and a concentration of oleuropein less than 60 μM.

### Claim at position 12

12: A method for improving wound healing comprising:
topically administering or transplanting to a subject in need of wound healing a composition comprising hydroxytyrosol and oleuropein and primary human vascular endothelial cells; and
reducing the time required for wound healing at least about 30% in comparison to a wound treated with the endothelial cells alone.

### Claim at position 13 (depends on 12)

13: The method according to claim 12, wherein the wound healing further comprises promoting keratinocyte and fibroblast proliferation and/or neovascularization.

### Claim at position 14 (depends on 12)

14: The method according to claim 12, wherein the endothelial cells are derived from umbilical cord blood and are umbilical cord stem cells, or a cultured medium conditioned by said umbilical cord stem cells.

### Claim at position 15 (depends on 12)

15: The method according to claim 12, wherein the ratio of hydroxytyrosol to oleuropein is from about 1:1 to about 10:1.

### Claim at position 16 (depends on 12)

16: The method according to claim 12, wherein the composition further comprises N-acetyl cysteine, glycine, taurine and L-proline.

### Claim at position 17 (depends on 16)

17: The method according to claim 16, wherein the weight ratio of N-acetyl cysteine to hydroxytyrosol is between 1:1 and 50:1, wherein the weight ratio of glycine to hydroxytyrosol is between 1:1 and 50:1, wherein the ratio of taurine to hydroxytyrosol is between 1:1 and 50:1, and wherein the weight ratio of L-proline to hydroxytyrosol is between 1:1 and 20:1.

### Claim at position 18 (depends on 12)

18: The method according to claim 12, wherein weight ratio N-acetyl cysteine to hydroxytyrosol is between 10:1 and 30:1, the weight ratio glycine to hydroxytyrosol is between 30:1 and 40:1, the weight ratio of taurine to hydroxytyrosol is between 20:1 and 50:1, and wherein the weight ratio of L-proline to hydroxytyrosol is between 1:1 and 10:1.

### Claim at position 19 (depends on 12)

19: The method according to claim 12, wherein the time required for healing at least 50% of a wound is reduced to below at least 8 hours.

### Claim at position 20

20: A composition for accelerating wound closure to improve wound healing comprising:
an effective amount of hydroxytyrosol, or oleuropein, or a combination of hydroxytyrosol and oleuropein; and
an effective amount of primary human vascular endothelial cells.
